Afinitor and Conjunctivitis - a phase IV clinical study of FDA data

Summary:

Conjunctivitis is reported as a side effect among people who take Afinitor (everolimus), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Sandostatin, and have Pancreatic neuroendocrine tumor.

The phase IV clinical study analyzes which people have Conjunctivitis when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Conjunctivitis?

Conjunctivitis (pink eye) is found to be associated with 1,298 drugs and 1,644 conditions by eHealthMe. Check the latest studies of Conjunctivitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

41,609 people reported to have side effects when taking Afinitor.
Among them, 69 people (0.17%) have Conjunctivitis.

Among these 69 people:

How long have people been on Afinitor when they have Conjunctivitis? *

What is the gender of people who have Conjunctivitis when taking Afinitor? *

female: 73.91 %
male: 26.09 %

What is the age of people who have Conjunctivitis when taking Afinitor? *

What are other drugs people take besides Afinitor? *

What are other side effects people have besides Conjunctivitis? *

Rashes (redness): 31 people, 44.93%
Dry Skin: 29 people, 42.03%
Injection Site Pain: 28 people, 40.58%
Abdominal Pain Upper: 27 people, 39.13%
Injection Site Mass: 26 people, 37.68%
Cough: 26 people, 37.68%
Malignant Neoplasm Progression (cancer tumour came back): 26 people, 37.68%
Hoarseness Or Changing Voice: 25 people, 36.23%
Skin Discoloration: 25 people, 36.23%
Injection Site Hypersensitivity: 25 people, 36.23%

What are the existing conditions these people have? *

Pancreatic Neuroendocrine Tumor: 17 people, 24.64%
High Blood Cholesterol: 15 people, 21.74%
Pancreatic Neuroendocrine Tumor Metastatic: 14 people, 20.29%
Uterine Fibroids (benign growths of the muscle inside the uterus): 10 people, 14.49%
Drowsiness: 10 people, 14.49%
Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 9 people, 13.04%
Neuroendocrine Tumor: 5 people, 7.25%
Brain Neoplasm Benign (non-cancerous tumour of brain): 5 people, 7.25%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 4.35%
Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 3 people, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and have Conjunctivitis?

- Check whether Conjunctivitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afinitor:

Afinitor (41,680 reports)

Conjunctivitis treatments and more:

Conjunctivitis (22,439 reports)

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctivitis:

Conjunctivitis (1,298 drugs)

Browse all the conditions that are associated with Conjunctivitis:

Conjunctivitis (1,644 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.